Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric carboxymaltose versus oral ferrous sulfate for antenatal anaemia in Malawi
ACTRN12618001268235Phase 3Completed
- Sponsor
- Kamuzu University of Health Sciences
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in anaemia and iron deficiency anemia (IDA) comparing Intravenous ferric carboxymaltose with Oral ferrous sulfate (2 arms). Primary endpoint: Maternal anaemia prevalence at 36 weeks gestation. Started Nov 2018; status: completed.
02
Drugs
ferric carboxymaltoseferrous sulfate
03
Conditions
anaemiairon deficiency anemia (IDA)
Beyond the preview
Go deeper on ACTRN12618001268235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001268235.